Global Approach to Hematologic Malignancies

Leslie Lehmann; Alaa El-Haddad; Ronald D Barr

doi:10.1016/j.hoc.2015.11.008

Global Approach to Hematologic Malignancies

Hematol Oncol Clin North Am. 2016 Apr;30(2):417-32. doi: 10.1016/j.hoc.2015.11.008. Epub 2016 Jan 4.

Authors

Leslie Lehmann¹, Alaa El-Haddad², Ronald D Barr³

Affiliations

¹ Pediatric Stem Cell Transplant, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA. Electronic address: Leslie_Lehmann@DFCI.Harvard.edu.
² Department of Pediatric Oncology, 1 Fostat Street, Sayda Zainab, Cairo 11757, Egypt.
³ Department of Pediatric Oncology, McMaster University, 1200 Main Street West, Hamilton, Ontario L8S 4J9, Canada.

PMID: 27040962
DOI: 10.1016/j.hoc.2015.11.008

Abstract

Treatment of childhood hematologic malignancies requires multidisciplinary care and reliable infrastructural support; creating a this structure in resource-poor settings remains challenging. Ideally therapy would be tailored to each region and disease. The development of research initiatives is essential. Acute lymphoblastic leukemia (ALL) and lymphomas are common in low- and middle-income countries; treatment is often resource intense but likely cost effective. Outcomes currently are worse than those reported in high-income countries. Chronic myeloid leukemia can be treated effectively with imatinib. Strategies to decrease the burden of therapy and robust palliative care programs are essential for optimal treatment of all afflicted children.

Keywords: Global; Hematologic malignancies; Leukemia; Low- and middle-income countries (LMIC); Lymphoma; Pediatric.

Publication types

Review

MeSH terms

Age Factors
Delivery of Health Care
Developing Countries
Disease Management
Global Health
Health Care Costs
Hematologic Neoplasms / diagnosis
Hematologic Neoplasms / epidemiology
Hematologic Neoplasms / therapy*
Humans
Incidence
Standard of Care
Treatment Outcome